Jul 18, 2023
Vancouver, British Columbia Jul 18, 2023 (Issuewire.com) - THC.CSE THCBF - OTC TFHD.F
THC BioMed Intl Ltd. ("THC BioMed" or the "Company"), a renowned innovator in the cannabis industry, is thrilled to announce its inclusion in the CSE Composite Index as of the market close on July 5, 2023.
The CSE Composite Index is administered by Solactive AG, a leading index provider serving 350 clients globally across Europe, America, and Asia. The index follows a set of robust policies and procedures, published on the CSE website, which are maintained by an Index Committee. This committee has the sole discretion to determine how policies and procedures are interpreted and can update them over time if deemed necessary.
"Our inclusion in the CSE Composite Index is a testament to our steady growth, financial performance, and commitment to our stakeholders," says THC Biomed CEO John Miller. "We are honored to join the ranks of other esteemed companies on this index and are excited about the increased visibility and potential enhanced liquidity this development may bring."
The inclusion in the CSE Composite Index marks a significant milestone for THC BioMed and serves as further recognition of the Company's commitment to cultivating and supplying high-quality cannabis products for both the medical and recreational sectors.
For more information about THC BioMed's business strategy, future, plans, and investment opportunities, please visit www.thcbiomed.com.
About THC BioMed
THC BioMed Intl Ltd. is a Cannabis Act Licensed Producer of medical and recreational cannabis. It is licensed to cultivate and sell dried, extract, edible, and topical cannabis. The Company is a pioneer in the cannabis industry, leading in scientific research and the development of products and services, with patient safety as a guiding principle.
Forward-Looking Information:
This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of THC BioMed. Forward-looking information is based on certain key expectations and assumptions made by the management of THC BioMed. Although THC BioMed believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because THC BioMed can give no assurance that they will prove to be correct.
Press Contact:
For additional information about THC BioMed's product lines or to stay updated on the Company's latest developments, visit www.thcbiomed.com.
For more information, media inquiries, or partnership opportunities, please contact:
President and CEO: John Miller
T: 1-844-THCMEDS
About THC BioMed
THC BioMed Intl Ltd. is a Cannabis Act Licensed Producer of medical and recreational cannabis. It is licensed to cultivate and sell dried, extract, edible and topical cannabis. The Company is on the leading edge of scientific research and the development of products and services related in the medical cannabis industry. Patient safety is not merely a goal but a guiding principle for THC BioMed.
Forward-Looking Information:
This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of THC BioMed. Forward-looking information is based on certain key expectations and assumptions made by the management of THC BioMed. Forward-looking statements in this release include that the Company will continue to broaden its reach across the Canadian market. Although THC BioMed believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because THC BioMed can give no assurance that they will prove to be correct.
The Canadian Securities Exchange (CSE) has not reviewed and does not accept responsibility for the adequacy or the accuracy of the contents of this release.
Source :THC Biomed International
This article was originally published by IssueWire. Read the original article here.
A 2026 Cost of Dying Report found direct cremation was now chosen for around one in five funerals.
MSPs have heard both the pros and cons of the government's plan to launch its first ever bond to the market.
"It's a really tough time for a lot of people," a sustainable food organisation says.
At an all-hands meeting with employees, Colette Kress sought to put the indiscretions of Nvidia’s co-founder, Jensen Huang, behind them.
Are you driving less? Car pooling? Using a different vehicle? Tell us how the 2026 energy shock has affected you.
Alibaba, the Chinese internet giant behind the company at the center of the Nvidia spy saga, has used its A.I. computing technology to aid a lab with links to China’s military.
Leaders in artificial intelligence and governments discussed America’s shifting politics, the reverberations of Jensen Huang’s ouster at Nvidia and more on Wednesday.
The multi-billionaire also said he was "not Maga", distancing himself from the political movement linked to Trump.
The artificial intelligence giant will become by far the largest publicly traded “public benefit corporation,” a structure that mandates it balance safety and profit.
Speaking alongside the Nasdaq chief Adena Friedman and the Polymarket founder Shayne Coplan, Vlad Tenev said regular investors should have access to more opportunities.
Graphics: The numbers behind China-US bilateral trade
The BBC's Samira Hussain speaks to a retail investor eagerly waiting for the AI company's stock to go live on Thursday.
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.